FDA launches unified platform for tracking side effects

The FDA on March 11 launched the Adverse Event Monitoring System, a consolidated platform that folds several existing reporting systems into a single searchable database. Officials say the system will standardize reporting, publish data in real time, and is expected to lower costs.

The Food and Drug Administration on March 11 unveiled the Adverse Event Monitoring System, a consolidated platform for tracking side effects reported after vaccines, drugs, and other products. The agency said the move replaces several older, fragmented reporting systems and will make data easier to search. FDA officials described the previous setup as costly and hard to use. The new platform is presented as a modernization effort that uses standardized reporting and some artificial intelligence for data work. Key details: - The system consolidates multiple legacy reporting platforms into a single Adverse Event Monitoring System and was made public on March 11. - Additional systems, including the Center for Tobacco Products Adverse Event Reporting System, are slated to be added in May. - The FDA receives more than two million reports of adverse events and medication errors each year and uses those reports for postmarket safety monitoring. - Officials said operating seven separate databases cost about $37 million per year; the new system is estimated to save roughly $120 million over five years. - The platform includes standardized reporting protocols and uses artificial intelligence for some data digitization and real-time publication, according to agency statements. - The system’s disclaimer notes that reports may contain inaccurate information, cannot provide the prevalence of events, and cannot conclusively link products with problems; the disclaimer also states that consumers should not stop or change medications without consulting a health care professional. Summary: The platform centralizes adverse event reports to make them more accessible to agency staff, researchers, and the public and is intended to support postmarket surveillance. FDA officials say the consolidation will reduce costs and improve data quality; additional reporting systems are planned to be integrated in May, and the agency has presented further timeline details as undetermined at this time.